Coloplast buys US woundcare manufacturer
This article was originally published in Clinica
Danish medical instruments producer Coloplast will purchase US-based Sween for $78.5 million in a deal expected to be completed at the end of February. Sween, which manufactures wound and skin care products, reported sales of $22.4 million in 1994, mostly in the US, generating an operating profit of $5.4 million.
You may also be interested in...
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.
China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.